Compare LAKE & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | STRO |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 85.0M |
| IPO Year | 2013 | N/A |
| Metric | LAKE | STRO |
|---|---|---|
| Price | $8.76 | $23.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | $17.33 | ★ $18.88 |
| AVG Volume (30 Days) | 78.8K | ★ 127.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,211,000.00 | N/A |
| Revenue This Year | $19.87 | $63.08 |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2554.14 | N/A |
| 52 Week Low | $7.77 | $0.52 |
| 52 Week High | $21.19 | $27.96 |
| Indicator | LAKE | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 63.80 |
| Support Level | $8.70 | $0.76 |
| Resistance Level | $9.67 | N/A |
| Average True Range (ATR) | 0.34 | 2.05 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 38.62 | 52.91 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.